Isolation, characterization, and in vitro propagation of infantile hemangioma stem cells and an in vivo mouse model

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Xu, Dan ^c   Teresa, M O ^b   Shartava, Archil ^c   Fowles, Taylor C ^c   Yang, Jianchang ^c   Fink, Louis M ^c   Ward, David C ^d   Mihm, Martin C ^e   Waner, Milton ^b   Ma, Yupo ^a,f  

^a STONY BROOK UNIVERSITY   (United States)

^b Vascular Birthmark Institute of New York   (United States)

^c NEVADA CANCER INSTITUTE   (United States)

^d UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Infantile hemangioma; SALL4; stem cells; tumor spheres

Indexed keywords

CD133 ANTIGEN; CD31 ANTIGEN; GLUCOSE TRANSPORTER 1; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN; RAPAMYCIN; SAL LIKE PROTEIN 4; TRANSCRIPTION FACTOR NANOG; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY HEMANGIOMA; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL ISOLATION; CELL LINEAGE; CELL PROLIFERATION; CELL RENEWAL; CONTROLLED STUDY; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; SCID MOUSE; STEM CELL; ANIMAL; CANCER STEM CELL; DISEASE MODEL; HEMANGIOMA; IMMUNOHISTOCHEMISTRY; MOUSE MUTANT; NEWBORN; NONOBESE DIABETIC MOUSE; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL GROWTH PROCESSES; DISEASE MODELS, ANIMAL; HEMANGIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT, NEWBORN; MICE; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; NEOPLASTIC STEM CELLS;

EID: 84855959111     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-54     Document Type: Article

References (32)

1. Cutaneous vascular anomalies. Mulliken JB, Semin Vasc Surg 1993 6 204 18 8305975 (Pubitemid 24001451)
2. A biologic approach to cutaneous vascular anomalies. Mulliken JB, Pediatr Dermatol 1992 9 356 7 10.1111/j.1525-1470.1992.tb00629.x 1492057 (Pubitemid 23004684)
3. Vascular anomalies. Mulliken JB, Fishman SJ, Burrows PE, Curr Probl Surg 2000 37 517 84 10.1016/S0011-3840(00)80013-1 10955029
4. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA, J Clin Invest 1994 93 2357 64 10.1172/JCI117241 7911127 (Pubitemid 24177146)
5. Hemangiomas in children. Maier H, Neumann R, N Engl J Med 1999 341 2018; author reply 9 10617398
6. Hemangiomas in children. Kushner BJ, N Engl J Med 1999 341 2018 author reply-9 10617398
7. Surgical removal of subglottic hemangiomas in children. Van Den Abbeele T, Triglia JM, Lescanne E, Roger G, Nicollas R, Ployet MJ, Garabedian EN, Narcy P, Laryngoscope 1999 109 1281 6 10.1097/00005537-199908000-00018 10443834 (Pubitemid 29379440)
8. Steroid therapy of a proliferating hemangioma: histochemical and molecular changes. Hasan Q, Tan ST, Gush J, Peters SG, Davis PF, Pediatrics 2000 105 117 20 10.1542/peds.105.1.117 10617714
9. Intralesional corticosteroid therapy for infantile hemangiomas. Sloan GM, Reinisch JF, Nichter LS, Saber WL, Lew K, Morwood DT, Plast Reconstr Surg 1989 83 459 67 10.1097/00006534-198903000-00009 2919200
10. Treatment of hemangiomas of infancy. Barrio VR, Drolet BA, Dermatol Ther 2005 18 151 9 10.1111/j.1529-8019.2005.05018.x 15953144 (Pubitemid 40934408)
11. Endothelial progenitor cells in infantile hemangioma. Yu Y, Flint AF, Mulliken JB, Wu JK, Bischoff J, Blood 2004 103 1373 5 14576053 (Pubitemid 38168651)
12. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. Khan ZA, Boscolo E, Picard A, Psutka S, Melero-Martin JM, Bartch TC, Mulliken JB, Bischoff J, J Clin Invest 2008 118 2592 9 18535669 (Pubitemid 351949786)
13. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Rafii S, Lyden D, Nat Med 2003 9 702 12 10.1038/nm0603-702 12778169 (Pubitemid 36749219)
14. Endothelial progenitor cell biology in disease and tissue regeneration. George AL, Bangalore-Prakash P, Rajoria S, Suriano R, Shanmugam A, Mittelman A, Tiwari RK, J Hematol Oncol 2011 4 24 10.1186/1756-8722-4-24 21609465
15. Are infantile hemangiomas of placental origin? North PE, Waner M, Brodsky MC, Ophthalmology 2002 109 633 4 10.1016/S0161-6420(02)01071-0 11949625 (Pubitemid 34270116)
16. Infantile hemangiomas: speculation on placental trophoblastic origin. Bree AF, Siegfried E, Sotelo-Avila C, Nahass G, Arch Dermatol 2001 137 573 7 11346335 (Pubitemid 32458439)
17. Congenital nonprogressive hemangioma: a distinct clinicopathologic entity unlike infantile hemangioma. North PE, Waner M, James CA, Mizeracki A, Frieden IJ, Mihm MC Jr, Arch Dermatol 2001 137 1607 20 11735711 (Pubitemid 34000909)
18. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Xu D, Alipio Z, Fink LM, Adcock DM, Yang J, Ward DC, Ma Y, Proc Natl Acad Sci USA 2009 106 808 13 10.1073/pnas.0812090106 19139414
19. Murine inner cell mass-derived lineages depend on Sall4 function. Elling U, Klasen C, Eisenberger T, Anlag K, Treier M, Proc Natl Acad Sci USA 2006 103 16319 24 10.1073/pnas.0607884103 17060609 (Pubitemid 44715194)
20. Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1. Zhang J, Tam WL, Tong GQ, Wu Q, Chan HY, Soh BS, Lou Y, Yang J, Ma Y, Chai L, Ng HH, Lufkin T, Robson P, Lim B, Nat Cell Biol 2006 8 1114 23 10.1038/ncb1481 16980957 (Pubitemid 44473607)
21. Sall4 interacts with Nanog and co-occupies Nanog genomic sites in embryonic stem cells. Wu Q, Chen X, Zhang J, Loh YH, Low TY, Zhang W, Zhang W, Sze SK, Lim B, Ng HH, J Biol Chem 2006 281 24090 4 10.1074/jbc.C600122200 16840789 (Pubitemid 44274183)
22. Generation of human induced pluripotent stem cells from dermal fibroblasts. Lowry WE, Richter L, Yachechko R, Pyle AD, Tchieu J, Sridharan R, Clark AT, Plath K, Proc Natl Acad Sci USA 2008 105 2883 8 10.1073/pnas. 0711983105 18287077 (Pubitemid 351723638)
23. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S, Cell 2007 131 861 72 10.1016/j.cell.2007.11.019 18035408 (Pubitemid 350138099)
24. Genome-wide analysis reveals Sall4 to be a major regulator of pluripotency in murine-embryonic stem cells. Yang J, Chai L, Fowles TC, Alipio Z, Xu D, Fink LM, Ward DC, Ma Y, Proc Natl Acad Sci USA 2008 105 50 19756 61 10.1073/pnas.0809321105 19060217
25. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Ma Y, Cui W, Yang J, Qu J, Di C, Amin HM, Lai R, Ritz J, Krause DS, Chai L, Blood 2006 108 2726 35 10.1182/blood-2006-02-001594 16763212
26. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Yang J, Chai L, Gao C, Fowles TC, Alipio Z, Dang H, Xu D, Fink LM, Ward DC, Ma Y, Blood 2008 112 3 805 13 10.1182/blood-2007-11-126326 18487508
27. SALL4 is a robust stimulator for the expansion of hematopoietic stem cells. Aguila JR, Liao W, Yang J, Avila C, Hagag N, Senzel L, Ma Y, Blood 2011 118 576 85 10.1182/blood-2011-01-333641 21602528
28. Enhanced Self-Renewal of Hematopoietic Stem/Progenitor Cells Mediated by the Stem Cell Gene Sall4. Yang J, Aguila JR, Alipio Z, Lai R, Fink LM, Ma Y, J Hematol Oncol 2011 4 38 10.1186/1756-8722-4-38 21943195
29. SALL4: finally an answer to the problem of expansion of hematopoietic stem cells? Aguila JR, Mynarcik DC, Ma Y, Expert Rev Hematol 2011 4 479 81 10.1586/ehm.11.46 21939414
30. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M, Cancer Res 2006 66 5549 54 10.1158/0008-5472.CAN-05-2825 16740688 (Pubitemid 43927103)
31. Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. Stahl A, Paschek L, Martin G, Gross NJ, Feltgen N, Hansen LL, Agostini HT, FEBS Lett 2008 582 3097 102 10.1016/j.febslet.2008.08.005 18703055
32. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. Yuan R, Kay A, Berg WJ, Lebwohl D, J Hematol Oncol 2009 2 45 10.1186/1756-8722-2-45 19860903